Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian DisorderGlobeNewsWire • Tuesday
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023GlobeNewsWire • 05/19/23
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 05/10/23
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of NeurologyGlobeNewsWire • 04/26/23
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 04/04/23
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 03/16/23
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer's DiseaseGlobeNewsWire • 03/14/23
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 03/08/23
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical TrialGlobeNewsWire • 02/16/23
Alterity's ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal ModelGlobeNewsWire • 01/30/23
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System AtrophyGlobeNewsWire • 01/25/23
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System AtrophyPRNewsWire • 01/09/23
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation ForumPRNewsWire • 01/03/23
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark OfficePRNewsWire • 12/29/22
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual MeetingPRNewsWire • 11/07/22
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual MeetingPRNewsWire • 10/26/22
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System AtrophyPRNewsWire • 10/13/22
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement DisordersPRNewsWire • 09/26/22
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System AtrophyPRNewsWire • 09/20/22
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in EuropePRNewsWire • 08/25/22